secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001802768-23-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q2 adj cash receipts $545M (+4%); raises 2023 guidance to $2.9-2.975B
--------------------------------------------------------------------------------

- Net cash from ops $608M (+6% YoY); Adjusted Cash Receipts $545M (+4%), Adjusted EBITDA $498M (+4%).
- Raised 2023 Adj Cash Receipts guidance to $2.900B-$2.975B from $2.85B-$2.95B, excluding new transactions.
- YTD announced transactions up to $1.7B, including $659M upfront; began share repurchases.
- CF franchise royalties +13% to $206M; Trelegy added $37M, Spinraza $13M; Imbruvica -22%, Xtandi -22%.
- Adjusted Cash Flow $512M (+6%) driven by EBITDA growth and higher net interest received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000022/0001802768-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000022/rprx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001802768-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer